CAMBRIDGE, Mass.–(BUSINESS WIRE)–KEW, Inc., a privately-held precision diagnostics company located in Cambridge, MA, USA, today announced the appointment of Jerry Williamson to the position of President and Chief Executive Officer and member of the Board of Directors effective March 13, 2017.
“Jerry’s leadership will accelerate the adoption of our platform by clinicians, hospitals and healthcare payers as they embrace precision medicine for cancer care.”
“We are delighted to welcome Mr. Williamson to KEW and are confident that his extensive experience in the diagnostic field will be of a great value to the Company, maximizing shareholder value and unlocking the company’s true intrinsic value,” commented Tuan Ha-Ngoc, Executive Chairman of Board. “We believe that Jerry’s knowledge and expertise are timely additions to boost the depth and breadth of our strategy to provide precision medicine testing to oncologists with our CANCERPLEX® family of products.”
“KEW has made remarkable progress in delivering a proven, next-generation sequencing platform of products and services for patients seeking therapy for their cancer,” stated Raju Kucherlapati, Ph.D., co-founder of KEW and Paul C. Cabot Professor of Genetics and Professor of Medicine, Harvard Medical School, and Director Emeritus, Harvard Medical School-Partners HealthCare Center for Personalized Genetic Medicine. “Jerry’s leadership will accelerate the adoption of our platform by clinicians, hospitals and healthcare payers as they embrace precision medicine for cancer care.”
“I am honored and excited to lead KEW on its vision to bring precision medicine to all physicians and patients worldwide. I believe that CANCERPLEX has the potential to substantially transform the treatment of cancer and improve the outcome of oncology therapy for patients,” said Mr. Williamson. “The team at KEW has created a unique product and service platform that is supported by data from thousands of patients which is continually updated based on new research and clinical outcomes. Patients tested with CANCERPLEX receive the highest quality precision medicine diagnostic testing,” added Mr. Williamson.
Jerry Williamson brings more than 30 years of commercial operating, business development and corporate management experience in the diagnostic and life science marketplace where he has held executive leadership roles responsible for value creation, growth and profitability. Most recently, Mr. Williamson was President and CEO of Metamark Genetics, Inc., a private molecular diagnostics company, which he joined in 2015. He has held positions of senior leadership for Flagship Ventures; Gentix, Ltd. which was sold to Danaher; Biacore, Inc. which was sold to GE Life Sciences; and Pyrosequencing, Inc. Jerry received a BS degree in Biochemistry from the University of Vermont and holds an MBA degree from Boston University.
About KEW, Inc.
KEW, Inc. is a privately-held comprehensive genomic profiling company with headquarters in Cambridge, MA, USA., dedicated to revolutionizing cancer care by providing therapeutic options based on an individual patient’s tumor genomic profile. CANCERPLEX® is KEW’s flagship clinical product family for sequencing and identifying applicable targeted therapies and clinical trials. The Company’s Powered-by-KEW? solutions offer expanded access to CANCERPLEX in partnership with local molecular pathology laboratories including KEW-qualified reagents, proprietary bioinformatics, a custom curated knowledge database, and comprehensive clinical reporting.